Travoprost intraocular implant lowers IOP

SAN ANTONIO – IDose-slow and iDose-fast from Glaukos were shown in a phase 2 prospective, randomized, clinical trial to lower IOP 32% and 33% at 12 weeks and maintain that level out to 12 months, according to Mitch Ibach, OD, here at the American Academy of Optometry meeting.

“The iDose will give us a way to pharmacologically manage patients with glaucoma, increasing patient compliance and decreasing adverse ocular events,” he said.

Disclosure: Ibach reports he is a consultant to and lecturer for Glaukos.